Eli Lilly (LLY)
(Delayed Data from NYSE)
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $886.00 -1.16 (-0.13%) 6:10 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $886.00 -1.16 (-0.13%) 6:10 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.
Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi
by Zacks Equity Research
Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.
3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson
Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs
by Kinjel Shah
Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.
Company News for Apr 28, 2021
by Zacks Equity Research
Companies in The News Are: LLY,ADM,UPS,CNC
Markets, GE Q1 Mixed; UPS Beats Big
by Mark Vickery
United Parcel Service (UPS) put up a legitimate blowout quarter for Q121, far surpassing expectations in the Zacks consensus.
Earnings Season in Full Swing
by Zacks Equity Research
Earnings Season in Full Swing
Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low
by Zacks Equity Research
Lilly (LLY) misses first-quarter estimates for both earnings and sales. It narrows 2021 forecast. Stock down in pre-market trading.
Eli Lilly (LLY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -11.79% and -1.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
What's in the Cards for Eli Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.
Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo
by Zacks Equity Research
Lilly (LLY) plans to stop COVID-19 treatment with bamlanivimab alone in the United States. Instead, a combination of bamlanivimab and etesevimab will be available for the same, a better therapy for variants.
Merck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir
by Zacks Equity Research
Merck (MRK) will start evaluating oral molnupiravir in non-hospitalized COVID-19 patients in a late-stage study. It stops MK-7110 development due to requirement of additional studies.
Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
by Zacks Equity Research
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development
by Kinjel Shah
FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.
AstraZeneca (AZN) Farxiga COVID-19 Study Fails to Meet Goal
by Zacks Equity Research
AstraZeneca's (AZN) phase III study on Farxiga in hospitalized COVID-19 patients with pre-existing health conditions fails to show statistical significance for the primary endpoint
The Zacks Analyst Blog Highlights: Oracle, Eli Lilly and BP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Eli Lilly and BP
Top Stock Reports for Oracle, Eli Lilly & BP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Eli Lilly and Company (LLY), and BP p.l.c. (BP).
Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.
Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes
by Kinjel Shah
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
Pfizer (PFE) Dermatitis JAK Inhibitor NDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of Pfizer's (PFE) candidate abrocitinib in atopic dermatitis by three months.
Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.